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Background: Federal regulations in the United States have shaped Institutional Review Boards (IRBs) to focus on
protecting individual human subjects. Health services research studies focusing on healthcare institutions such as
hospitals or clinics do not have individual human subjects. Since U.S. federal regulations are silent on what type of
review, if any, these studies require, different IRBs may approach similar studies differently, resulting in undesirable
variation in the review of studies focusing on healthcare institutions. Further, although these studies do not focus
on individual human subjects, they may pose risks to participating institutions, as well as individuals who work at
those institutions, if identifying information becomes public.
Discussion: Using two recent health services research studies conducted in the U.S. as examples, we discuss
variations in the level of IRB oversight for studies focusing on institutions rather than individual human subjects.
We highlight how lack of IRB guidance poses challenges for researchers who wish to both protect their subjects
and work appropriately with the public, journalists or the legal system in the U.S. Competing interests include the
public’s interest in transparency, the researcher’s interest in their science, and the research participants’ interests in
confidentiality. Potential solutions that may help guide health services researchers to balance these competing
interests include: 1) creating consensus guidelines and standard practices that address confidentiality risk to
healthcare institutions and their employees; and 2) expanding the IRB role to conduct a streamlined review of
health services research studies focusing on healthcare institutions to balance the competing interest of
stakeholders on a case-by-case basis.
Summary: For health services research studies focusing on healthcare institutions, we outline the competing
interests of researchers, healthcare institutions and the public. We propose solutions to decrease undesirable
variations in the review of these studies.Background
Due to several high-profile abuses of human research
subjects in the 20th century, the United States Office of
Human Research Protections (OHRP) was established to
oversee regulations that prevent future abuses. These
regulations, widely called the “Common Rule”, guide
Institutional Review Boards (IRBs) to review research
that involves “human subjects”, which are defined as indi-
viduals about whom data is being collected through inter-
vention or interaction with the study or about whom
identifiable, private information is obtained [1].* Correspondence: anna.chodos@ucsf.edu
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unless otherwise stated.Since OHRP regulations and IRBs focus on human
subjects research, health services research focusing on
healthcare institutions such as hospitals or health sys-
tems have experienced highly variable IRB review of
their research. Unlike human subjects research, there are
currently no regulations and few guidelines for the re-
view of research focusing on institutions. This may be-
come increasingly problematic in the current era of
health care reform within the U.S. as more studies are
conducted that focus on health systems. Below, we re-
count two recent examples of health services research
studies which experienced widely divergent levels of IRB
review in order to highlight potential competing inter-
ests of various stakeholders. Finally, we will conclude
with solutions that may help balance these valid compet-
ing interests.tral. This is an Open Access article distributed under the terms of the Creative
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Examples of variation in review of non-human subjects
research by IRBs
Study 1: Lagu and colleagues contacted subspecialist
practices to request an appointment for a fictional obese
and hemiparetic patient, for whom “full and equal access
to healthcare services and facilities” is required under
the Americans with Disabilities Act (ADA) [2]. Twenty
two percent said they were unable to accommodate or
see this patient. The IRB chose to review this study.
They mandated that the authors contact the practices
after the completion of data collection to debrief them
and let them know they had been included in a research
study. When advised of this research, several practices
expressed anger that they had been included in research
without their knowledge. (from personal conversation
with Dr. Lagu, permission granted to use) Furthermore,
the IRB instructed the authors to destroy identifying in-
formation prior to publication so that individual clinics
in violation of the ADA could not be identified [3-5].
After publication, the state Attorney General’s office
called Dr. Lagu, asking for identifying information. She
informed them that her staff had destroyed the identify-
ing information under the direction of the IRB. (from
personal conversation with Dr. Lagu, permission granted
to use).
Study 2: Rosenthal and colleagues used a “secret shop-
per” approach to determine the cost of a total hip arthro-
plasty at twenty top-ranked U.S. orthopedic hospitals
(according to the US News and World Report) as well as
two randomly selected hospitals from each state. They
found that prices were difficult to obtain and when ob-
tained, showed a nearly ten-fold variation between the
most-and least-expensive hospitals [6]. Rosenthal and col-
leagues submitted this study for IRB review, but their IRB
declined to review, stating that this was not human sub-
jects research and thus beyond their purview. After publi-
cation, the authors were contacted by journalists asking
them to identify which hospitals were included from each
state and what the costs were with each hospital. They
were also contacted by hospital administrators of the
twenty top-ranked hospitals asking about the cost quoted
by their own hospital as well as the name of the person
who provided this information. Without IRB oversight,
the researchers released some information on a case-by-
case basis. Specifically, they did not identify any individ-
uals who provided cost information, but did provide the
cost quoted by a hospital to its own hospital administra-
tors. (from personal conversation with Dr. Cram, senior
author on study, permission granted to use).
Why were these two studies handled so differently by
different IRBs? Should both or neither have been reviewed?
Did the two IRBs get it right and only the Lagu study
needed review?Minimizing risks to non-human subjects
Although neither the Lagu nor Rosenthal study had hu-
man subjects, both studies had the potential to expose
research participants to risk. If the subspecialty practices
included in the Lagu study were identified and fined, the
front office staff could have been reprimanded or even
fired. Similarly, the hospital staff that provided cost data
in the Rosenthal study could also have been disciplined
by hospital leadership. Thus, these institutions employed
people who could have been harmed via involuntary re-
search participation though they were not the direct
subjects of study.
In market research in the United Kingdom, guidelines
for “secret shopper” studies recommend that the identity
of participants (who are not always consented) should be
protected and “the competitor staff or organisation must
not suffer any detrimental effect as a result of a mystery
shopping exercise” [7]. However, these guidelines are not
widely recognized in health services research and without
consistent IRB involvement health services researchers
must often navigate these complex issues without external
oversight.
Need for guidance in researchers’ interactions with
journalists and the legal system
In the Lagu study, if the IRB had not mandated that
identifying information be destroyed, what would have
been Dr. Lagu’s options when the Attorney General’s of-
fice called? Most health services researchers would feel
uneasy divulging research data that may put research par-
ticipants at risk. However, most health services researchers
would be uncomfortable declining a request from an
Attorney General. The IRB’s foresight in requiring that
identifying information be destroyed prior to publication
allowed Dr. Lagu to avoid this dilemma. Further, the IRB
provided her with support from a system of institutional
oversight that insulated her from practices as well as the
Attorney General.
Because the Rosenthal study was not reviewed, when
they were contacted by journalists asking for the identity
of hospitals, they had to decide what to divulge on a
case-by-case, ad hoc basis. They did not benefit from an
IRB review that could have guided them prior to re-
quests for information from journalists. Their decision
to provide limited information in specific cases was very
reasonable and their decision to minimize identifying
hospitals was probably appropriate. However, additional
institutional guidance could have prepared Rosenthal
and colleagues and led them to consider the potential
risks to their research subjects if the subjects were pub-
licly identified. This in turn would have clarified before
publication what information should and should not be
divulged to the media. Although the researchers’ ap-
proach toward confidentiality was reasonable, they did
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identifying information prior to being faced with media
attention.
Competing interests of the public, research participants
and health services researchers
The U.S. public funds and participates in a substantial
portion of research and they have a reasonable expect-
ation to access specific research results. Research sub-
jects often have an interest in maintaining confidentiality
of specific information. For example, in the Lagu study,
mandating the destruction of information that identifies
practices may have been ethical to protect them and the
staff that work there. However, by hindering the identifi-
cation of practices that illegally discriminated against
Americans with disabilities, the IRB’s actions left some
with the perception that they were more interested in
protecting IRB protocols and physician practices than
disabled Americans. Paula Span, a New York Times jour-
nalist, noted that “shredding the results creates the im-
pression that the IRB values its protocols over the public
interest” [8]. Along with the public and research subjects,
U.S. researchers have an interest in conducting high-
impact research.
The interests from the three stakeholders will often be
at odds. Since no clear guidelines for review of non-
human subjects research exists, it is often left to the in-
dividual researcher to balance these competing interests
on an ad hoc basis, as occurred with the Rosenthal study.
The history of research abuse suggests that although the
vast majority researchers will act appropriately and ethic-
ally, few will not. External review is one way to ensure that
abuses are minimized.
Recommendations
To appropriately balance the valid competing interests
of the public, non-human research subjects and re-
searchers, we propose the following two recommenda-
tions. First, consensus guidelines, for U.S. researchers or
more broadly, should be developed that address when
external review is necessary and detail how competing
interests should be balanced.
Guideline development should engage health services
researchers, ethicists, representatives from healthcare in-
stitutions, research funders and the public to get a
broad-based understanding of the competing interests
involved. Ideally, guidelines should start to describe how
these competing interests should be balanced. Specific cir-
cumstances where the risk of harms are greater (e.g. legal
action) should be considered.
Second, IRBs in the U.S. should expand their role to
review non-human subjects research. Expanding IRB
oversight could be costly and labor intensive, and con-
tribute to increased review burden that already lengthenstime from research proposal to active study. However,
one middle ground would be to have specialized review
sections staffed with health services researchers with ex-
perience in non-human subjects research. In most insti-
tutions, IRBs are best positioned to provide external
research oversight to researchers, given their diverse
membership and the similarities of health services re-
search to some types of clinical and medical research.
Summary
The public supports or participates in most health services
research. The public, journalists and the legal sector con-
sume health services research. Health services research is
growing as the focus on quality of care and transparency of
cost becomes more central to the U.S. health care system.
Researchers therefore stand at the interface of health ser-
vices research, the public and the law. For health services
research to continue to grow and thrive, clearer principles
should be developed to guide individual researchers and
support IRBs in balancing these valid competing interests.
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